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A proportion of patients presenting with hypertrophic cardiomyopathy (HCM) have a 
diagnosis of cardiac amyloidosis. Hereditary transthyretin amyloid cardiomyopathy (hATTR-
CM) is caused by more than 100 mutations in the TTR gene. Our aim was to study the 
prevalence of potentially amyloidogenic TTR gene variants in a whole-exome sequencing 
(WES) study of a large cohort of patients with HCM. 
Methods and results  
770 consecutive HCM probands underwent WES and clinical characterization. Patients with 
rare or known pathogenic variants in TTR underwent 99mTechnetium labeled 3,3-
diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and were retrospectively re-
assessed for the presence of clinical  features of amyloidosis.  
Two patients had rare TTR variants of unknown significance and four had the known 
pathogenic p.V122I (p.V142I) variant (one homozygous and also heterozygous for a likely 
pathogenic MYL3 variant and another double heterozygous for a likely pathogenic MYBPC3 
variant). Four out of 6 patients with TTR variants underwent DPD scintigraphy; the only 
positive study for cardiac amyloidosis was in the patient with the homozygous p.V122I 
(p.V142I) variant. 
Conclusions 
Pathogenic TTR variants are rare in carefully assessed patients with HCM and may occur in 
double heterozygosity with sarcomere protein gene mutations.  The lack of evidence for an 
amyloidosis phenotype in all but one TTR mutation carrier illustrates the importance of 
complete clinical evaluation of patients meeting HCM criteria that harbour pathogenic TTR 
mutations.  
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Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease that affects 0.2% of the 
population and which predisposes to sudden cardiac death and heart failure. It is most 
commonly caused by mutations in genes encoding for sarcomere and related proteins, with 
a small proportion caused by syndromic diseases and inborn errors of metabolism. [1] 
Transthyretin (TTR) amyloidosis is a multisystem disorder caused by aggregation of TTR 
amyloid fibrils in various tissues. There are two classical presentations of the disease: 
transthyretin familial amyloid polyneuropathy (TTR-FAP), which primarily affects the 
peripheral nerves, and TTR cardiomyopathy (TTR-CM), which presents most commonly as 
hypertrophic cardiomyopathy. [2] TTR-CM can be an acquired disorder of the elderly or a 
hereditary condition caused by over 100 mutations in the TTR gene, of which at least 22 are 
associated predominantly with TTR-CM. [2], [3], [4] The point mutation valine 142 to 
isoleucine (p.V122I (p.V142I)) is the most common TTR-CM variant, with a prevalence of 
about 3–4% in the African-American population. [2] In a very recent report [5] of a United 
Kingdom cohort of more than 4000 patients referred due to a diagnostic suspicion of 
amyloidosis, the most frequent pathogenic variant was p.V122I (p.V142I); nearly 50% of the 
patients with this mutation were of Afro-Caribbean ancestry, the remaining originating from 
different regions of Africa, mostly the West. 
Recent studies suggest that a substantial number of patients with heart failure with 
preserved ejection fraction [6], hypertrophic cardiomyopathy [7] and aortic stenosis [8] have 
evidence for wild type TTR cardiac amyloidosis.  
The aim of this study was to study the prevalence of amyloidogenic TTR gene variants in a 
prospective whole-exome sequencing study of nearly 800 patients with hypertrophic 
cardiomyopathy in whom cardiac amyloidosis was not suspected at first assessment. 
 5 
Methods 
Study population and design, clinical evaluation and sample collection 
This was an observational, prospective single-centre study. All patients gave written 
informed consent in accordance with the protocol approved by the regional ethics 
committee (15/LO/0549) and received genetic counselling in accordance with international 
guidelines. The study population comprised unrelated and consecutively evaluated patients 
with HCM referred to the Inherited Cardiovascular Disease Department at Barts Heart 
Centre, London, UK and before 2015 to the Inherited Cardiovascular Disease Unit at The 
Heart Hospital, UCLH, London, UK. The samples used in this study were collected from 2013 
to 2018.  
Clinical evaluation included a personal and family history, physical examination, 12 lead ECG, 
echocardiography, symptom limited upright exercise testing with simultaneous respiratory 
gas analysis (cardiopulmonary exercise test) and ambulatory ECG monitoring as previously 
described [9]. HCM was diagnosed in probands when the maximum left ventricular (LV) wall 
thickness (MLVWT) on 2D echocardiography measured 15 mm or more in at least one 
myocardial segment or when MLVWT exceeded 2 standard deviations (SD) corrected for 
age, size and gender in the absence of other diseases that could explain the hypertrophy [1]. 
In individuals with unequivocal disease in a first-degree relative, diagnosis was made using 
extended familial criteria for HCM [1]. Ethnicity was self reported and classified using a 
modified National Health Service ethnicity questionnaire. Patients were evaluated every 6–
12 months or earlier if there was a clinical event. Initial evaluation and follow-up data were 
collected prospectively and registered in a relational database.  
Patients with previously clinically suspected or confirmed inherited metabolic, syndromic or 
infiltrative diseases including amyloidosis were excluded from the WES study. When a TTR 
variant was detected, hospital records were reanalysed to determine the presence of 
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phenotypic characteristics of cardiac TTR-amyloid. These included, a) low-voltage and/or 
“pseudoinfarct” pattern, and/or bundle branch block (BBB)/conduction disease on 12 lead 
ECG; b) concentric left ventricular hypertrophy on echocardiography and/or biventricular 
hypertrophy and/or base-apical myocardial strain gradient pattern; c) typical late gadolinium 
enhancement on cardiac magnetic resonance imaging (MRI); d) carpal tunnel syndrome. 
Patients still under follow-up and with rare/novel variants or the pathogenic p.V122I 
(p.V142I) variant underwent 99mTc-DPD (99mTechnetium labelled 3,3-diphosphono-1,2-
propanodicarboxylic acid) scintigraphy to confirm cardiac amyloidosis [10].  
DNA Extraction and whole-exome sequencing (WES) library preparation 
DNA was extracted from whole blood using the QIAamp Midi / Mini Kit by Qiagen following 
the relevant protocol. Sample library preparation from Genomic DNA was done as per the 
Agilent SureSelectQXT Target Enrichment Illumina multiplexed sequencing protocol. We 
used Agilent SureSelectXT Human Exon V6 following the manufacturer’s protocol to capture 
targeted exonic regions. Exome sequencing of the enriched libraries occurred on the 
Illumina Hiseq4000 platform at a minimum of 30x coverage, using standard manufacturer’s 
protocols.  
Bioinformatic analysis of WES data 
Sequence reads alignment against the reference human genome (UCSC hg19) was 
performed using NovoAlign (Novocraft Technologies Sdn Bhd). Picard 
(http://picard.sourceforge.net/) was used for duplicate reads removal, format conversion, 
and indexing.  Recalibration of base quality scores and performance of local realignments 
around possible indels was done with Genome Analysis Toolkit (GATK) 
(https://www.broadinstitute.org/gatk/).  HaplotypeCaller 3.1 package in GATK was used for 
variants calling and generation of a multi-sample joint genotyping. Variant annotation was 
 7 
done with ANNOVAR [11] and Variant Effect Predictor (VEP) tool from Ensembl [12].  For the 
in silico prediction of pathogenicity of missense variants we used multiple bioinformatics 
tools, including HumVar-trained PolyPhen-2 model [13], SIFT [14], and MutationTaster [15]. 
Variants were also annotated with minor allele frequencies reported in the Genome 
Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/) [16]. TTR variants were 
annotated with transcript NM_000371. 
Variant filtering and further downstream annotation 
Variants identified by WES with a minor allele frequency (MAF) higher or equal to 0.0001 
(0.01%) in gnomAD were removed from further analysis, except for more common variants 
known to be pathogenic. Variants outside of the coding and splice-site regions as well as 
synonymous variants not predicted to alter splicing were also filtered and excluded. 
Remaining genetic changes were prioritized by their predicted functional effect, including 
likelihood to result in a loss-of-function (stop gain, frameshift deletion or insertion) or 
altering splicing. Ingenuity® Variant AnalysisTM software 
(https://www.qiagenbioinformatics.com/ products/ingenuity-variant-analysis) from 
QIAGEN, Inc. was used for further downstream annotation, including:  presence and 
classification of the variants in the ClinVar database, American College of Medical Genetics 
(ACMG) classification and presence in the published literature. 
Copy number variants (CNVs) analysis 
The analysis of large rearrangements in the coding regions of genes was done using a read 
depth strategy designed to overcome biases associated with sequence capture and high-
throughput sequencing . This set of tools is implemented in the package ExomeDepth (freely 




The study cohort comprised 770 patients, 515 (67%) males, aged 49.3±15.9 years at 
diagnosis (median 51.6); 64.3% were white, 11% black. Thirty-two percent had variants with 
a MAF < 1x10-4 in eight sarcomeric genes which are robustly associated with HCM (MYH7, 
MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, ACTC1). Twenty-one patients carried multiple 
rare sarcomere variants, including 9 compound heterozygotes (5 in MYBPC3, 3 in MYH7 and 
1 in TNNI3) and 12 double (digenic) heterozygotes. 
Six patients had candidate TTR variants detected.  One (p.R21Q (p.R41Q)) was previously 
described in the literature and is classified as a variant of unknown significance (VUS) in 
Clinvar [18].  Another (p.R103H (p.R123H)) is also listed as a VUS in Clinvar. The four 
remaining patients (0.5% of the cohort) had the pathogenic p.V122I (p.V142I) variant. One 
patient was homozygous for this variant and also carried a rare and likely pathogenic MYL3 
variant (p.R94H) and another was double heterozygous with a rare and likely pathogenic 
MYBPC3 variant (p. R495Q). 
No copy number variants in TTR were detected. 
Demographic, electrocardiographic, imaging and genetic data for all 6 patients are shown in 
table 1. Four were males (67%), one patient was white (17%).  
The patient with the homozygous p.V122I (p.V142I) mutation was the only individual to have 
some clinical features consistent with cardiac amyloidosis on retrospective chart review 
(table 1).  Two other patients with a p.V122I (p.V142I) variant had mild conduction 
abnormalities (left BBB in one and first degree AV block in another). Low ECG voltages were 
not present in any patient with a TTR variant. In terms of cardiac imaging, only the 
homozygous p.V122I (p.V142I) patient had an echocardiogram and MRI potentially 
suggestive of amyloid due to LVH with systolic dysfunction, restrictive pattern and unusual 
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pattern of late gadolinium enhancement. None had concentric hypertrophy. 
Four of the six patients with TTR variants underwent DPD scintigraphy (two of the patients 
still under follow-up in our centre with a p.V122I (p.V142I) variant and those with rare TTR 
variants).  Only the patient with a homozygous p.V122I (p.V142I) mutation was positive, 
with a Perugini grade 3, confirming cardiac amyloidosis.  
 
Discussion 
Transthyretin (TTR) is a protein encoded by a single gene (TTR) that is synthesized almost 
exclusively by the liver and which circulates predominantly as a homotetramer, along with a 
very small amount of dissociated monomers. Amyloidogenesis begins with dissociation of 
the TTR tetramer into dimers and folded monomers. Unfolding of these species leads to the 
formation of soluble oligomers and polymerisation into amyloid fibrils within tissues. [2]TTR 
mutations destabilise the TTR tetramer and in some cases accelerate the rate of 
dissociation. More than 100 amyloidogenic mutations have been described, all of which are 
inherited as autosomal dominant traits with incomplete penetrance. The most common TTR 
mutation is V30M, endemic in parts of Portugal, Sweden and Japan where it typically causes 
polyneuropathy. A number of TTR variants including p.V122I (p.V142I) are associated with a 
predominant cardiac phenotype. [2],[3] The spectrum of cardiac involvement in ATTR ranges 
from asymptomatic conduction disease to cardiomyopathy and refractory heart failure.  
[3],[4], [19] 
We undertook screening and annotation of the TTR gene in an unprecedentedly large cohort 
of consecutive HCM patients studied with whole-exome sequencing and characterized the 
cardiac phenotypes of patients who carried rare or known pathogenic variants.  
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Several studies have shown that wild-type ATTR is frequently missed as a cause of 
ventricular dysfunction in patients with heart failure with preserved ejection fraction and 
aortic stenosis. [6],[8]  but most of the published studies focusing on hereditary TTR-amyloid 
(hATTR) were designed to establish the prevalence of cardiac involvement in patients with 
an already known diagnosis of hATTR or wtATTR. Two previous studies have examined the 
prevalence of hATTR in patients with HCM and no prior suspicion of TTR-CM, but neither 
used whole-exome sequencing. [20],[21]. In a Dutch cohort of 345 genotype-negative 
patients with HCM [21] two individuals were found to harbour a p.V30M (p.V50M) and a 
p.V122I (p.V142I) mutation. However, no demographic data, scintigraphic or biopsy data 
were provided. In a second French study, the overall prevalence of TTR pathogenic variants 
in 298 patients with HCM was 5.7%, the majority of which was caused by p.V122I (p.V142I). 
As anticipated, most patients with this mutation were of African ancestry (6/8).  
In our study, two of the identified rare TTR variants are variants of unknown significance but 
likely to be non-pathogenic (both had negative DPD scans). This means that the prevalence 
of amyloidogenic TTR variants in our cohort is only ~0.5%.  
The explanation for the dramatic difference in prevalence with the French study is 
speculative, but is likely related to different ethnic composition (for example, a higher 
proportion of black patients in the French cohort (23% versus 11%), referral bias and the 
exclusion of HCM phenocopies in our cohort prior to WES [7].  
A final consideration is the age of recruited patients. The median age of the French cohort 
was 62 years (74 years in TTR-amyloid and 61 years in other hypertrophic cardiomyopathy 
patients without TTR variants) whilst the median age of our WES cohort was 52 years. Only 
9% of our cohort is above 70 years of age and 16% above 65. Furthermore, our patients 
carrying a p.V122I (p.V142I) mutation were only between 36-61 years. Given that hTTR-
cardiac amyloid penetrance is age dependent [22],[5] these differences in age distribution 
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may also explain the discrepancy with previous studies.  
Interestingly, the only patient with a positive DPD scan was homozygous for p.V122I 
(p.V142I) and also heterozygous for a likely pathogenic mutation in MYL3. Another patient 
with a heterozygous p.V122I (p.V142I) mutation also carried a pathogenic mutation in 
MYBPC3, but this patient had been lost to follow-up and we could not perform a DPD scan. 
In patients carrying both a pathogenic sarcomere variant and p.V122I (p.V142I), a double hit 
effect cannot be excluded, but the phenotype of the two patients in whom this was present 
is not obviously dissimilar to the other HCM patients for the whole cohort. From the clinical 
point of view, these co-existent sarcomere variants are very relevant to inform family 
screening.  
None of the patients with the pathogenic p.V122I (p.V142I) TTR mutation had low voltages. 
However, low voltages have been reported as infrequent and of low sensitivity in TTR-
cardiomyopathy and other parameters such as the total QRS score divided by indexed LV 
mass (g/m2) have been proposed as earlier markers of amyloid myocardial infiltration in this 
context. [23] Similarly, none had a pattern of concentric hypertrophy on imaging. 
Nevertheless, asymmetric hypertrophy, traditionally described as more typical of sarcomeric 
hypertrophic cardiomyopathy, was also found to be the most common pattern of 
hypertrophy in TTR cardiomyopathy in a recent publication. [24] 
Endemic pathogenic mutations such as p.V30M (p.V50M), p.T60A (p.T80A), p.L111M 
(p.L131M) and p.I68L (p.I88L) [2],[4],[3] were also not found in our patients, most likely due 
to differences inherent to the geographical origin of our cohort. In summary, both regional 
and ethnic bias have contributed to the presence of p.V122I (p.V142I) as the only detected 
pathogenic TTR variant.   
Our data show that in a large HCM cohort where cardiac amyloidosis has been previously 
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excluded after careful clinical assessment, TTR-amyloid is a rare finding. We do not suggest 
WES should be applied to HCM patients as a clinical screening strategy to exclude TTR-
amyloid. However, it is very reasonable to include TTR gene as part of the initial genetic 
testing panel used in these patients, as it is current standard practice in most referral 
centres, given the relevant implications of an amyloid diagnosis and the overlap in terms of 
history, ECG and imaging that can exist between sarcomere and amyloid cardiomyopathy, 
precluding a strong a priori clinical suspicion (i.e. no obvious clinical “red-flags” in some 
patients). Additionally, this genetic sequencing strategy also allows the detection of the rare 
patients where pathogenic sarcomere variants are co-inherited with TTR mutations, with 
relevant implications in terms of genetic counseling and cascade/predictive genetic testing. 
 
Conclusions 
In this series of carefully phenotyped patients with HCM, pathogenic TTR variants occurred 
in less than 1% of all individuals. In accord with the published literature, the only mutation 
to be identified, p.V122I (p.V142I), was predominantly found in black individuals and was 
often non-penetrant.  
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Table 1. Genetics, demographics and extra-cardiac red-flags. 




















Extra cardiac “red- 
flags” 
Other variants 
1 R41Q 8.12E-06 0.00006497 VUS Asian  38 m 2018 no no 
2 R123H 7.218e-5 0.00066583 VUS Black 42 f 2018 no no 
3 V122I (V142I) 0.001505 0.00006497 pathogenic Asian 45 m 2018 no no 






0.001505 0.01601897 pathogenic Black 61 m 2018 
yes – carpal tunnel 
syndrome 
MYL3 p.R94H 
6 V122I (V142I) 0.001505 0.01601897 pathogenic Black 43 f 2018 no no 











Table 2. Main features of the ECG, imaging and clinical data. 




1 SR, LBBB (post-miectomy) 
ASH and apical HCM, 
MLVWT 19mm 
NA (ICD) Neg NSVT 
2 
SR, LVH; Deep inverted T 
waves laterally 





MLVWT 18mm, minor LGE 
Neg NSVT 
3 
SR, Prolonged PR; LVH; Deep 
inverted T waves laterally  
ASH and apical, MLVWT 
22mm; LVOTO 





4 SR, bi-atrial enlargement 
ASH, MLVWT 20 mm; 
LVOTO 







SR, left axis deviation, LBBB-
like, no progression R waves 
V1-V3  
ASH with low EF (45%), 
MLVWT 17mm; low GLS    
(-13%); Diastolic 
dysfunction type 3 
ASH MLVWT 17mm; LA 
severely dilated; moderate 




SR, LVH; Deep inverted T 
waves laterally 
ASH, MLVWT 25; low GLS 
(-6%); LVOTO 
ASH MLVWT 25mm; patchy 
extensive LGE 
Neg NSVT 
ASH: asymmetrical septal hypertrophy; DPD: 99mTechnetium labeled 3,3-diphosphono-1,2-propanodicarboxylic acid 
scintigraphy; EF: ejection fraction; GLS: global longitudinal strain; ICD: implantable cardioverter defibrillator; LA: left atria; LBBB: 
left bundle branch block; LGE: late gadolinium enhancement; LVH: left ventricular hypertrophy; LVOTO: left ventricular outflow 
tract obstruction; MLVWT: maximal left ventricular wall thickness; MRI: Magnetic resonance imaging; NSVT: non-sustained 
ventricular tachycardia; NA: not available; SR: sinus rhythm. 
 
 
 
